NNDM News & Events

Stock futures are markedly higher this morning as investors return from the weekend focused on a preliminary U.S.-Iran peace agreement that could reopen the Strait of Hormuz and significantly ease pressure on global energy markets.Brent crude has dropped to roughly three-month lows after the announced agreement, easing concerns about supply disruptions and helping reduce inflation fears that had weighed on stocks throughout the spring.AI-related stocks are rebounding after last week's volatility, supported by falling Treasury yields and renewed optimism that the Federal Reserve may not need to become more aggressive on rates if energy-driven inflation continues to cool. Investors are also closely watching the strong post-IPO performance of SpaceX, which has helped reignite enthusiasm.This week's key event is the Federal Reserve meeting under Chair Kevin Warsh. Markets overwhelmingly expect no change in interest rates, but traders will scrutinize the Fed's outlook for inflation, growth, and the possibility of future rate hikes. Falling oil prices have reduced some of the urgency around inflation concerns heading into the meeting.In pre-market trading, S&P 500 futures rose 1.29%, Nasdaq futures rose 2.08% and Dow futures rose 1.03%.Check out this morning's top movers from around Wall Street, compiled by The Fly.HIGHER -SpaceXup 6%, building on the advance seen after Friday's IPOParamount Skydanceup 3% after the Antitrust Division of the U.S. Department of Justice gave approval to the proposed acquisition of Warner Bros. DiscoveryNano Dimensionup 2% after entering into a non-binding term sheet for a proposed business combination with Infinite EpigeneticsRokuup 1% after announcing a definitive agreement under which Fox will acquire Roku for $160.00 per share in a combination of cash and Fox Class A common stock, valuing Roku at approximately $22B in enterprise valueUP AFTER EARNINGS -Comtechup 6%Coda Octopusup 7%DOWN AFTER EARNINGS -Canopy Growthdown 1%LOWER -Elicio Therapeuticsdown 62% after announcing its AMPLIFY-7P study did not meet its pre-specified primary DFS endpoint in the intent-to-treat populationTraws Pharmadown 17% after reporting that the planned test of tivoxavir marboxil in a Phase 2a human influenza challenge study has been deferred due to a negative review of the program by the United Kingdom's Medicines and Healthcare Products Regulatory AgencyFoxdown 14% after announcing a definitive agreement under which Fox will acquire Roku for $160.00 per share in a combination of cash and Fox Class A common stockFiservdown 6% after noting Mike Lyons has stepped down as CEO and member of the board of directors to become CEO of Truist FinancialCheesecake Factorydown 1% after Northcoast downgraded the stock to Neutral, citing valuation

Nano Dimension announced it has entered into a non-binding term sheet for a proposed business combination with Infinite Epigenetics. Under the term sheet, the proposed transaction contemplates that Nano Dimension, or a successor publicly traded company, would acquire 100% of the equity interests of Infinite Epigenetics through a merger, consolidation or other transaction structure to be mutually agreed by the parties. Upon closing of the proposed transaction, if any, the combined company is expected to operate under the Infinite Epigenetics name and continue trading on the Nasdaq Capital Market under the proposed ticker symbol (IEAI). Existing Nano Dimension shareholders are expected to retain a minority ownership interest in the combined company based on a stated value for Nano shares that reflects a 20% premium to Nano Dimension's estimated net cash at closing, subject to final negotiation and execution of a definitive agreement. The parties expect that the combined company will have over $400M in cash at closing. Additionally, the pre-combination Nano Dimension shareholders would receive a contingent value right entitling them to certain net proceeds, if any, received by a newly formed entity and liquidation trust from the disposition of certain Nano legacy assets following the closing of the combination. The term sheet provides for a 30-day period of mutual exclusivity, during which Nano Dimension will conduct confirmatory due diligence on Infinite Epigenetics, and the parties will finalize the terms of a definitive merger agreement. Matthew Dawson, co-founder and CEO of Infinite Epigenetics, is expected to serve as CEO of the combined company. The board is expected to include representatives designated by Nano, as well as Infinite Epigenetics leaders and directors. Nano Dimension expects to announce additional details regarding the proposed business combination if and when a definitive agreement is executed.

Stratasys (SSYS) announced that it has entered into a definitive agreement to acquire MarkForged, a wholly owned subsidiary of Nano Dimension (NNDM), in an all-cash transaction valued at $42.5M, subject to customary adjustments. In 2025, Markforged generated approximately $70M in revenue, including their Metal Binder Jetting product line, which Nano Dimension will retain. The transaction is expected to close in the second half of 2026, subject to customary closing conditions and regulatory approvals.

Nano Dimension issued the following letter to shareholders providing a business update and commenting on the Schedule 13D/A filing by Murchinson Ltd. and certain of its affiliates. "Nano Dimension and its Board of Directors remain fully focused on executing the Company's previously announced strategic alternatives review process to maximize shareholder value and believe shareholders should understand the facts and implications surrounding the recent actions of Murchinson Ltd. and certain of its affiliates... The Board is rejecting this latest attempt by Murchinson to seize control of the Company through disruption and pressure tactics... It has become clear to the Board that Murchinson's objective is not long-term value creation, but rather control of Nano's balance sheet and strategic direction without offering shareholders a premium or presenting a coherent long-term value creation plan. The Board believes this approach creates significant risk for all shareholders... The Board believes these efforts are beginning to gain meaningful traction and that stability and continuity are critical at this stage of the process. Importantly, these efforts are being pursued with a focus on creating value for all shareholders - not advancing the interests or agenda of any single shareholder or activist group... The Board remains fully committed to acting in the best interests of all shareholders and will continue to pursue every opportunity to maximize shareholder value through disciplined governance and responsible stewardship of the Company's assets."